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Abstract
Catheter-based left atrial appendage closure is an evolving therapy for the prophylaxis 
of thromboembolic complications in nonvalvular atrial fibrillation patients, which are 
ineligible for long-term oral anticoagulation. For this indication, it is recommended by 
the current European guidelines. This review of the existing literature should facilitate 
the understanding of the therapy’s practical implications. It presents a clinical approach 
toward a correct patient selection, gives an overview of the different devices and the 
procedural aspects, reflects differences and benefits between several postprocedural regi-
mens for device surveillance as well as antithrombotic medication and rounds off with a 
summary of the relevant studies concerning efficacy and safety outcome measures.
Keywords: atrial fibrillation, left atrial appendage closure, thromboembolism, stroke, 
oral anticoagulation
1. Atrial fibrillation, thromboembolic risk, and prevention
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a significant burden of 
disease. The prevalence is age-dependent and increases with the age [1, 2]. While it is uncom-
mon in patients younger than 40, about 10% of the 80-year olds are affected [1, 2]. AF nowa-
days is prevalent in about 3% of the western population, but it is estimated that the incidence 
will rise over the next decades linked to the increased life expectancy [1, 2]. As in the case of 
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other cardiovascular diseases, males are more frequently affected than females [1, 2]. Though 
AF rather rarely causes acute fatal complications at the time of onset, medium-term prognos-
tic complications such as left ventricular dysfunction, cognitive decline, and utmost impor-
tant cerebral ischemic stroke change AF toward a harmful cardiac disease [3]. AF accounts 
for 20–30% of all strokes and many patients are diagnosed with AF for the first time after 
they have been affected by a stroke (so-called “silent” AF) [3]. Therefore, the prognosis of AF 
patients is substantially determined by the risk for thromboembolic events.
1.1. Thrombogenesis during atrial fibrillation
Due to the electrical storm occurring on the atrial myocardium and the irregular ventricular 
excitation during AF episodes, the atrial mechanical function is impaired. Consecutively, the 
atrial cavities are distended, the intraatrial pressure is increased and the blood flow is reduced. 
These mechanisms connected to the Virchow’s triad are only part of a multifactorial network 
leading to thrombogenesis also including the expression of prothrombotic factors [4–6]. The 
changes are especially prominent in the blind-ended left atrial appendage (LAA) located in 
front of the anterior wall of the left atrium (LA) with its ostium between the left upper pul-
monary vein and the mitral valve annulus [6, 7]. The walls of the LAA are highly trabeculated 
which renders them thrombogenic [7]. Four general LAA shapes are described in the literature, 
i.e., the chicken wing, cactus, windsock, and cauliflower shaped LAA (Figure 1A), whereby the 
data of the proportional distribution substantially vary within the literature [8]. Certain LAA 
morphologies were identified as an independent risk factor for thromboembolic events [9, 10]. 
Altogether, in patients with nonrheumatic AF more than 90% of all atrial thrombi occur in the 
left atrial appendage (Figure 1B) [11].
Figure 1. (A) The four different left atrial appendage morphologies with (a) the chicken wing, (b) the cactus, (c) the 
windsock and (d) the cauliflower type. (B) Echocardiographic visualization of a left atrial appendage thrombus (*).
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1.2. Pros and cons of an oral anticoagulation therapy for thromboembolic prophylaxis
Because of these interrelationships, the risk stratification for thromboembolic events and a 
risk-based indication for thromboembolic prophylaxis are important pillars in the AF patient’s 
therapy. For this purpose, the CHA
2
DS
2
-VASc score is recommended (IA) [3]. It incorporates 
all the relevant risk factors for stroke in AF patients: congestive heart failure (+1), hyperten-
sion (+1), age (65–74 +1 and ≥ 75 years +2, respectively), diabetes mellitus (+1), prior stroke, 
transient ischemic attack (TIA) or thromboembolism (+2), vascular disease (+1), and female 
gender (+1). According to the current European guideline recommendations, a thromboem-
bolic prophylaxis by oral anticoagulants is recommended for all males with a CHA
2
DS
2
-VASc 
score ≥ 2 and for all females with a CHA
2
DS
2
-VASc score ≥ 3 (IA). Furthermore, this prophy-
laxis should be considered in males with a CHA
2
DS
2
-VASc score = 1 and in females with a 
CHA
2
DS
2
-VASc score = 2 according to the individual characteristics and the patient’s prefer-
ences (IIaB) [3]. The evaluation of biomarkers, e.g., high-sensitive troponins and natriuretic 
peptides, can be helpful in this context (IIbB) [3]. For several decades, vitamin K antagonists 
have served as the gold standard for thromboembolic prophylaxis in AF patients [12], but 
their clinical use is limited by an increased and substantial bleeding risk which especially 
harms vulnerable patients [13, 14]. The vulnerability to bleedings can be assessed by the 
HAS-BLED score including arterial hypertension (+1), abnormal renal (+1) or liver (+1) func-
tion, prior stroke (+1), bleeding history or predisposition (+1), labile international normal-
ized ratio (INR) (+1), age > 65 (+1) and drugs (+1) or alcohol (+1) concomitantly [15]. While 
dual antiplatelet agents failed to be an effective and safe alternative to vitamin K antagonists 
[16], recently, non-vitamin K antagonist oral anticoagulants (NOACs), i.e., dabigatran, riva-
roxaban, apixaban, and edoxaban, were gaining ground [17–20]. In the current European 
guidelines, these substances are preferentially recommended for all eligible nonvalvular AF 
patients (IA) [3]. However, stoked by a higher incidence of gastrointestinal bleedings in com-
parison to vitamin K antagonists and other side effects [21], patients’ adherence to NOAC 
therapy was also shown to be limited [22].
1.3. Alternatives to an oral anticoagulation therapy
By the implication of the LAA as a primary source of thrombi for thromboembolic events 
in nonvalvular AF, locoregional techniques to avoid thromboembolism out of the LAA 
were developed. Besides the surgical resection of the LAA during open heart surgery and 
the epicardial LARIAT® Suture Delivery Device (SentreHEART, Redwood City, CA, USA) 
with limited evidence for efficacy and safety [23, 24], six CE-marked devices for transvenous 
catheter-based LAA closure are currently available: the WATCHMAN™ left atrial appendage 
closure device (Boston Scientific, Natick, MA, USA), the AMPLATZER™ Cardiac Plug (ACP) 
and its next generation the AMPLATZER™ Amulet™ left atrial appendage occluder (both St. 
Jude Medical, Minneapolis, MN, USA), the WaveCrest™ LAA Occlusion System (Coherex 
Medical, Salt Lake City, UT, USA), the Occlutech® LAA occluder (Occlutech, Jena, Germany) 
and the LAmbre™ LAA Closure System (Lifetech Science, Shenzhen, China), respectively. 
However, only the WATCHMAN™ device was compared to oral anticoagulation (OAC), 
i.e., warfarin, in a prospective randomized controlled trial (RCT) in patients eligible for OAC 
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[25]. Long-term data revealed a noninferiority and superiority compared to OAC for prevent-
ing the combined outcome of stroke, systemic embolism, and cardiovascular death as well 
as superiority for cardiovascular and all-cause mortality [26]. Moreover, the PREVAIL trial 
stated adequate safety of the WATCHMAN™ procedure [27]. The efficacy and safety of other 
devices were exclusively evaluated by observational studies.
2. The interventional left atrial appendage closure
2.1. Indications and decision-making
Worthy of note, the patients with the strongest indication for a thromboembolic prophy-
laxis often also have a relevantly increased bleeding risk, represented by a major intersec-
tion of the risk factors included in the CHA
2
DS
2
-VASc and the HAS-BLED score. Based on 
the different approval procedures the necessary indications for the interventional closure of 
the LAA vary geographically and will subsequently be presented in the European context. 
The current European guidelines recommend the interventional LAA closure (LAAC) as 
an alternative to OAC for nonvalvular AF patients with an indication for OAC but on the 
other hand contraindications for a long-term treatment with this substances (IIbB) [3]. They 
note that, for example, patients with a prior life-threatening bleeding without a reversible 
cause may have a contraindication for long-term OAC [3]. However, further examples for 
the practical implementation are not given. Furthermore, the indication is impeded by the 
fact that numerous patients that formerly have been considered unsuitable for long-term 
OAC nowadays can take an oral prophylactic medication due to an adequate management 
[3, 28].
As the two currently available RCTs in the field of interventional LAAC only included, by 
their nature, patients which were eligible for long-term OAC [25, 27], they do not appear 
suitable for the identification of guideline-conform reasons for an interventional approach. 
The best practical help may be provided by the EHRA/EAPCI expert consensus statement 
[29] from which the presented decision-making algorithm is derived (Figure 2). If possible 
contraindications for a long-term anticoagulation arise and the individual CHA
2
DS
2
-VASc 
score is low, i.e., 1 in males and 2 in females, the necessity for OAC should be strictly checked 
in a risk-tailored approach with the aid of biomarkers (cf. 1.2 and [3]). Only patients with a 
persisting indication should be further evaluated.
In a first step, patients, which are presented for the LAAC evaluation, should be divided into 
those who are per se eligible for OAC and those who are not. All eligible patients should 
be well informed about the guideline recommendation for a prophylaxis by OAC, preferen-
tially by a NOAC whenever possible. Some patients, however, will still refuse to take one 
of these substances due to various reasons, e.g., subjective anxiety, increased professional 
bleeding risk, OAC intolerance due to other side-effects than bleedings or noncompliance 
with OAC. If so, patients’ refusal may be considered as an adequate contraindication for 
long-term OAC.
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Two prospective, observational studies demonstrated safety and efficacy of LAAC in patients 
who were ineligible for any OAC [30, 31]. This indication is depicted most clearly by the 
formulation in the European guidelines [3]. It covers, in particular, prior life-threatening 
bleedings according to Bleeding Academic Research Consortium (BARC) type 3 [32] without 
a reversible or controllable cause. This includes bleedings due to angiodysplasia, amyloid 
Figure 2. Decision-making algorithm derived from Ref. [29]; # = 1 in males or 2 in females; † = HAS-BLED score ≥ 
3, bleeding risk not reflected by the HAS-BLED score, prolonged triple therapy or recurrent minor bleedings under 
(N)OAC, e.g., gastrointestinal bleedings.
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angiopathy, malignoma, chronic inflammatory bowel disease, thrombocytopenia, platelet 
dysfunctions, or other coagulation disorders as well as recurrent falling in the course of epi-
lepsy or frailty [30, 31, 33, 34]. As well as for the patients refusing OAC, it must be stated, that 
a postinterventional temporary intake of at least two antiplatelet agents regularly followed 
by a lifelong single antiplatelet therapy is mandatory in most centers and cases of relevant 
 postinterventional bleedings under dual antiplatelet therapy (DAPT) can be found in litera-
ture [35, 36]. There is growing evidence for the efficacy of a single antiplatelet therapy fol-
lowing LAAC but a strategy of discontinuation of any antiplatelet therapy is still based on 
single-center experience [37–40]. In this context, at least the bleeding risk under acetylsalicylic 
acid (ASA) should be included in the considerations [29, 41].
In other patients, the risk for a severe bleeding under long-term OAC might be estimated 
unacceptably high even without the existence of a prior life-threatening bleeding event. These 
patients with an increased HAS-BLED score (≥ 3 according to [29]) or recurrent minor bleed-
ings (according to BARC type 1 and 2 [32]) require a thorough individual risk-benefit profile 
evaluation by taking into account the lowered bleeding event rates under NOAC therapy. 
But, thereby, especially patients with recurrent minor gastrointestinal (GI) bleedings as well 
as those with a risk for GI bleedings perform very poor [21]. Due to the practical necessity of 
a postinterventional lifelong ASA intake, again, the risk for bleedings under ASA should be 
determined [29, 41]. In addition to the above-mentioned causes for bleedings and the ones 
depicted by the HAS-BLED score, a prolonged triple therapy due to a complex coronary artery 
disease may be a particularly relevant indication in this group of patients. AF patients with a 
highly impaired renal function, i.e., glomerular filtration rate <15 ml/min, or those with chronic 
renal replacement therapy reflect special cases. In these patients, both a high bleeding risk and 
a high stroke risk are associated with an increased mortality [42, 43]. These patients cannot 
be treated by NOACs and the benefit of a treatment with vitamin K antagonists is controver-
sially discussed [44–46]. The value of an interventional closure of the LAA in these patients 
cannot be stated at this point. However, promising data concerning safety and efficacy exist 
in patients with chronic kidney disease compared to the estimated TIA, stroke and bleedings 
rates of the collective even in patients with an end-stage renal disease [47].
Special cases where a LAAC may be indicated without a contraindication for long-term OAC 
are patients with thromboembolic events despite a well monitored treatment with OAC even 
after switching to another substance or to higher INR values. In these patients, and especially 
if it is likely that the thrombus originated from the LAA, LAAC can be an alternative or an 
additional treatment to OAC [29].
In a European multicenter observational trial consecutively including slightly more than 1000 
patients with a LAAC procedure, 47% had suffered a major hemorrhage, 35% were defined as 
being prone to a high bleeding risk, 22% had an indication for a triple therapy, 16% suffered 
a stroke under OAC, and 8% had an elevated risk of falling [33]. By reflecting the above- 
presented indications in a real-life cohort, it was emphasized that in some patients the combi-
nation of several reasons resulted in the indication.
In a second step, after establishing the indication, the patients’ medical documents should be 
screened for contraindications for catheter-based LAAC. These are valvular or rheumatic AF 
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as, in these patients, thrombi do not originate from the LAA in up to 60% of cases [11, 48], con-
traindications for catheterization and transseptal puncture such as active infection, left atrial 
thrombus or tumor as well as the presence of a closure device on the atrial septal puncture 
site and indications for lifelong OAC besides AF such as mechanical heart valves, recurrent 
pulmonary embolism and deep vein thrombosis.
In a third step, if these contraindications can be excluded, anatomical feasibility should be 
checked by thorough two- and three-dimensional transesophageal (TEE) measurements prior 
to the intervention [49–51]. Not only the absence of a thrombus in the LA and LAA must 
be confirmed but also LAA dimensions must fulfill certain device-specific requirements. 
Ultrasound contrast agent use may facilitate the detection of a thrombus [52]. Therefore, 
the LAA is visualized and measured in multiple views (0, 45, 90 and 135°) at the end of the 
atrial diastole when the LAA volume is largest to avoid undersizing. First of all, the maximal 
ostial width is measured from a point right next to the left circumflex coronary artery or the 
mitral valve annulus to a point 1–2 cm from the tip of the left superior pulmonary vein limbus 
(Figure 3). While the orifice usually is oval shaped, the largest diameter is of procedural inter-
est for the WATCHMAN™ device implantation. For the Amplatzer™ devices a so-called land-
ing zone 10–12 mm from the orifice into the LAA is important. Furthermore, the LAA depth 
is measured perpendicular to the ostial plane. The WATCHMAN™ device is unsuitable if the 
depth-width ratio is < 1, the Amplatzer™ Amulet™ is limited to a depth of ≥ 7.5 mm. An orifice 
of 30 mm for the WATCHMAN™ device and a landing zone of 31 mm for the Amplatzer™ 
Figure 3. Echocardiographic measurements prior to the left atrial appendage closure; solid line = orifice diameter, 
dashed line = depth, dotted line = landing zone.
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Amulet™, respectively, are the upper limitations concerning the LAA width. Large secondary 
lobes should be assessed accurately as they might impede the complete sealing of the LAA 
orifice, especially when a second large lobe branches off close to the ostium.
In cases where the LAA evaluation by TEE is difficult, especially if multiple lobes are present, 
further imaging methods, e.g., computed tomography (CT) angiography, may help to ensure 
correct measurements [53–57]. In case of an existing LAA thrombus, several attempts with 
different substances can become necessary to resolve it [58], but this effort will not be possible 
in patients with absolute contraindications to even short-term (N)OAC treatment.
2.2. Device types and procedural aspects
The five CE-marked devices for catheter-based LAAC can be divided into two groups, the 
ball and the disk type, respectively. The WATCHMAN™ device, the WaveCrest™ system 
and the Occlutech® occluder form the ball-type group while the Amplatzer™ devices and the 
Lambre™ system form the disk-type group. All devices consist of a self-expanding nitinol mesh 
with wires to anchor in the LAA walls and they are covered by different patches. The disk-
type group is characterized by a so-called waist connecting a proximal disk with a distal lobe. 
Newer LAAC devices are optimized for intraprocedural repositioning by retractable anchors, 
for instance, to facilitate the procedure in complex anatomies. The WaveCrest™ system has a 
foam coat to minimize residual leaks after implantation. Operators evaluated the ACP’s “paci-
fier principle” was particularly user-friendly, which might be reflected by high success rates in 
the early trials [29]. Furthermore, it might have advantages in anatomies with two large main 
lobes originating from one ostium. But these assertions are mainly based on expert opinions 
and ongoing studies will have to further evaluate the individual advantages of the latest devel-
opments on the device market and the value of a certain device type for different morphologies.
The catheter-based LAAC procedure (Figure 4) is usually performed under deep conscious 
sedation or general anesthesia. Antibiotic prophylaxis is recommended prior to the intervention. 
The procedure is guided by fluoroscopy, angiography, and TEE. Some centers use additional 
intracardiac echocardiography (ICE) [59]. The correct device type and size (10–30% larger than 
the measured diameter to allow device stabilization by compression forces) is chosen by the 
above mentioned preinterventional TEE or CT measurements. In Seldinger technique, vascular 
access is taken via the right femoral vein and the transseptal puncture is performed in a stan-
dard fashion in the posterior and inferior atrial septum. This allows to easily access the LAA 
ostium. If a patent foramen ovale is present, this “ natural” way can also be used for transseptal 
crossing provided it is suitable for the LAA access [33]. Again, the freedom from thrombus is 
confirmed by angiography via an intraatrial pigtail catheter (right anterior oblique 30°/cranial 
30°) and by TEE or ICE. Prior to the transseptal puncture, unfractionated heparin is adminis-
tered to achieve an activated clotting time >250 s. Via the transseptal wire the device delivery 
sheath (8–14 French) is inserted. It is particularly important to avoid air embolism by flushing 
the sheath and the device with isotonic saline prior to the insertion. All devices are preinstalled 
on the catheters. The device is deployed by retracting the delivery sheath over the device which 
then self-expands. The deployment is conducted by fluoroscopy and echocardiography. In case 
of incorrect positioning, all current devices can be repositioned by  retraction into the delivery 
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sheath prior to device releasement. When the correct landing position is achieved, the stable 
device anchoring is confirmed by a so-called “tug test” and correct sealing of the LAA ostium is 
illustrated by angiography and color Doppler imaging. After complete device deployment and 
before TEE retraction, a pericardial effusion should be ruled out. It is naturally clear that the 
procedural steps might slightly vary between the different devices. In relation to procedural 
success, an operator-related learning curve could be demonstrated [33, 60, 61]. Procedures 
combined with other cardiac interventions, e.g., percutaneous coronary intervention, closure 
of a persistent foramen ovale or an atrial septum defect, atrial fibrillation ablation, or even 
transcatheter aortic valve implantation, are not untypical in clinical practice [33]. The value of 
combined procedures especially of those which both require a transseptal puncture is currently 
not completely elucidated. Moreover, despite the knowledge of the chicken wing morphology 
being a highly challenging LAA anatomy [62], procedural characteristics and outcomes related 
to different LAA morphologies still remain to be evaluated.
2.3. Postprocedural measures and antithrombotic regimens
It is a frequent practice to perform a chest X-ray as well as a transthoracic echocardiography 
24 hours after the procedure to reconfirm the device position and the absence of a pericardial 
Figure 4. Fluoroscopic and angiographic images of the left atrial appendage closure procedure. (A) Angiographic 
illustration of the cauliflower shaped left atrial appendage (*); # = delivery sheath. (B) The WATCHMAN™ device 
(+) is pushed forward through the delivery sheath. (C) The device (+) is implanted in the left atrial appendage. (D) 
Stable anchoring is confirmed by pulling the device (+) in the direction of the white arrow (“tug test”). (E) The correct 
sealing of the left atrial appendage by the device (+) is illustrated by angiography. (F) The released left atrial appendage 
occluder (+).
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effusion prior to the patients’ discharge from hospital. The average length of stay is around 
2–5 days [63, 64]. Endocarditis prophylaxis is usually considered prior to at-risk procedures 
for 6 months after the implantation.
The follow-up visits as well as the imaging modalities for device surveillance are closely 
linked to the initiated postinterventional antithrombotic regimen. Subsequently, different 
regimens for the most common devices, the WATCHMAN™ and the Amplatzer™ devices, 
respectively, are presented. For the other devices, regimens must be adopted by having 
regard to the instructions for use.
If the patient is eligible for short-term OAC after the WATCHMAN™ device implantation, it 
is usually conducted for 45 days reflected by the two RCTs [25, 27], two observational stud-
ies with NOACs [65, 66] and the instructions for use. TEE is performed after this period to 
rule out device thrombus prior to switching to DAPT and again after 6 months when switch-
ing from DAPT to ASA therapy is intended. In the PROTECT-AF trial, 86% of all implanted 
patients could be discontinued with warfarin after 45 days and 92% after 6 months as the 
TEE criterion (peridevice leak <5 mm) was met. In the more recent PREVAIL trial, 92 and 
98% of all implanted patients were able to discontinue warfarin after 45 days and 6 months, 
respectively. While there is no evidence for increased thromboembolic event rates associated 
to peridevice leaks <5 mm independent of OAC discontinuation based on a limited source of 
evidence [67], peridevice leaks ≥ 5 mm remain an indication for continuation or reinitiation of 
OAC whenever possible or for a second occlusion attempt [29, 68].
As many patients are ineligible to even short-term OAC, postinterventional regimens without 
OAC prescription had been urgently needed. Therefore, two smaller prospective observational 
studies evaluated a DAPT after LAAC and revealed adequate efficacy and safety for such regi-
men with the WATCHMAN™ device and the ACP [30, 31]. This regimen is also adopted in the 
instructions for use for the Amplatzer™ devices. DAPT was prescribed 1–6 months after the 
procedure and then switched to an indefinite single antiplatelet therapy. As above-stated, the 
efficacy of a single antiplatelet therapy following LAAC for specific high-risk patients appears 
adequate but the complete discontinuation of antithrombotic treatment at some point is based 
on limited experience [37–40]. While the optimal timing for  postinterventional device surveil-
lance cannot be completely justified by the existing literature, a follow-up between a mini-
mum of 1.5 and a maximum of 6 months as a compromise between the fast switch to minimal 
antithrombotic therapy after ensuring adequate LAA occlusion and the secure identification 
of device-related thrombi appears reasonable [69]. Platelet count, CHA
2
DS
2
-VASc score and 
reduced ejection fraction were identified as risk factors for device-related thrombi under DAPT 
[70]. Although the thrombus-associated stroke rate appears low [61], it is recommended to 
resolve it by a new initiated or continued anticoagulation whenever possible [29]. Additional 
clinical visits or imaging procedures may not be mandatory apart from study protocols, but 
by bearing in mind late device embolizations [71] (cf. 2.4) and the underlying cardiovascular 
disease of the intervened patients, it appears reasonable to follow them up regularly.
TEE currently remains the gold standard for postimplant device surveillance. Magnetic reso-
nance tomography imagining is hindered by artefacts from the device and especially in light 
of radiation exposure and the need for contrast agent use [72], the value of CT angiography 
compared to TEE for postimplant imaging has not been finally clarified [73, 74].
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2.4. Procedure-related complications and short-term outcome
Procedure-related complications are mainly associated with bleedings such as pericardial effu-
sion and tamponade and access site complications, i.e., hematoma, overt bleeding, AV fistula, 
and pseudoaneurysm. Moreover, periinterventional TIA and stroke as well as early device 
embolization and air embolism have also been reported. Additional late device embolizations 
have been observed and there are several surgical and interventional techniques to retrieve 
an embolized device in relation to its location [71, 75]. Table 1 summarizes the reported com-
plications from the most representative studies for the most common devices. The presented 
Study Patients in the 
treatment arm 
[n]
Successful 
implantation 
[%]
Relevant 
pericardial 
effusion [%]
Access site 
complication 
and other major 
bleeding [%]
TIA or stroke; 
hemorrhagic 
stroke [%]
Early device 
embolization 
[%]
WATCHMAN™ device
Holmes et al. 
[25]
463 88 4.8 3.5 1.1; 0.2 0.6
Reddy et al. 
[61]
460 95 2.2 0.7 0.0 0.0
Reddy et al. 
[31]
150 95 1.3 2.0 0.7 1.3
Holmes et al. 
[27]
269 95 0.4 0.7 0.7 0.7
Boersma et al. 
[34]
1019 99 0.1 1.1 0.0 (0.3 
between days 
8 and 30)
0.2
Amplatzer™ devices
Park et al. 
(ACP) [84]
143 96 3.5 n/a 2.1 1.4
Lam et al. 
(ACP) [78]
20 95 0.0 0.0 n/a 0.0
Urena et al. 
(ACP) [30]
52 98 0.0 3.8 1.9 1.9
Gloekler et 
al. (ACP and 
Amulet™) [76]
100 96 6.0 0.0 0.0 5.0
Tzikas et al. 
(ACP) [33]
1047 97 1.2 1.2 0.9 0.8
Abualsaud et 
al. (ACP and 
Amulet™) [77]
59 98 0.0 n/a 0.0 0.0
Berti et al. 
(ACP and 
Amulet™) [64]
110 96 2.7 0.9 0.9 0.0
Table 1. Implantation success and procedural safety; n/a = not applicable; TIA = transitory ischemic attack.
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data usually refer to events within the first 7 days following the procedure. No procedure-
related death occurring during the first week and only one procedure-related death (0.1%) 
within 30 days after the WATCHMAN™ device implantation was recently reported from the 
large multicenter observational EWOLUTION registry [34], a low rate, which also could be 
recently observed in a multicenter observational registry for the ACP [33]. The implantation 
success (≥ 95%) was highly satisfactory most recently. Comparing the periprocedural safety, 
the first and second generation Amplatzer™ devices appear equal [76, 77]. Not only for the 
procedural success but also for the reduction of overall complications, a learning curve over 
time was obvious [33, 60, 61].
2.5. Medium- and long-term outcome
As mentioned in the beginning, the WATCHMAN™ device was shown to be superior (poste-
rior probability 96.0%) for the combined outcome of stroke, systemic embolism and cardiovas-
cular death compared to a warfarin treatment in a long-term follow-up to the PROTECT-AF 
trial with a 2:1 randomization for the device implantation [26]. After a mean follow-up of 
3.8 years (2621 patient-years) the primary annual event rate was 2.3% in the device versus 
3.8% in the warfarin group (rate ratio 0.60; 95% credible interval 0.41–1.05) [26]. In the initial 
PROTECT-AF trial with a follow-up of 1065 patient-years, only the noninferiority could be 
demonstrated (posterior probability >99.9%) [25]. The primary annual event rate in the device 
group was 3.0 versus 4.9% in the warfarin group (rate ratio 0.62; 95% credible interval 0.35–1.25). 
The study is limited by a high dropout rate in the control groups as well as by collecting a per 
se OAC eligible collective with a low stroke risk (CHADS
2
 score 2.2 ± 1.2).
Under the conditions of an equal study protocol but of a higher CHADS
2
 score of 2.6 ± 1.0 
the PREVIAL trial failed to reach noninferiority for the primary efficacy outcome within 18 
months [27]. Only for the stroke and systemic embolization rate >7 days after randomization 
noninferiority could be stated. But the key message of this trial was the lower rate of safety 
events compared to PROTECT-AF despite a high proportion of untrained operators (25%) 
and a more inclusive definition of safety events compared to PROTECT-AF event rates were 
still lower (annual rates of 4.2 versus 8.7%, respectively; p = 0.004).
With a total of 5931 patient-years, a meta-analysis of the PROTECT-AF trial, the PREVAIL 
trial and the subsequent registries confirmed noninferiority for the predefined combined pri-
mary efficacy endpoint compared to warfarin treatment [79]. Annual event rates were 2.7 
and 3.5%, respectively (hazard ratio 0.79; 95% credible interval 0.53–1.20 ; p=0.22). Worthy of 
note, only after subtracting the procedure-related strokes from the total number of strokes, 
the event rates in the device and the warfarin group were no longer significantly different 
(hazard ratio 1.56; 95% credible interval 0.78–3.09; p = 0.21). Reflecting a bleeding benefit, 
hemorrhagic stroke was significantly less frequent in the device group (0.15%; 95% credible 
interval 0.07–0.40) compared to the warfarin group (0.61%; 95% credible interval 0.55–1.70) 
(hazard ratio 0.22; 95% credible interval 0.08–0.61; p = 0.004).
The largest data set for the ACP was published by Tzikas et al. (prospective collection of 
the data and retrospective analyzation). He reports, after 1349 patient-years of follow-up, 
an annual systemic thromboembolism rate of 2.3% [33]. In terms of safety, an annual rate 
of major bleeding of 2.1% was registered. Based on a mean CHA
2
DS
2
-VASc score of 4.5 ± 
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1.6 and a mean HAS-BLED score 3.1 ± 1.2, this meant a risk reduction of 59% for systemic 
 thromboembolism and 61% for major bleeding respectively, compared to the rates predicted 
by the scores.
Postinterventional DAPT was mainly proven effective and safe by the prospective observa-
tional studies of Reddy et al. (WATCHMAN™) [31] and Urena et al. (ACP) [30]. Annual event 
rates for all-cause stroke and systemic thromboembolism were 2.3 and 3.4%, respectively. 
Reddy et al. found an annual rate for hemorrhagic stroke of 0.6%. Urena et al. observed an 
annual major bleedings rate of 3.4%. Thus, these outcome measures were completely com-
parable to the event rates in the RCTs including OAC eligible patients. The mean/median 
CHA
2
DS
2
-VASc scores of 4.4 ± 1.7 and 5 (4–6), respectively, thereby correspond to a high-risk 
collective.
Concerning alternatives to vitamin K antagonists and DAPT following LAAC, two recently 
published studies reported data for the strategy of a single antiplatelet therapy after LAAC. 
After a total of 265 patient-years an annual stroke rate of 2.3% was observed by Korsholm 
et al. under a single ASA therapy [40]. The mean CHA
2
DS
2
-VASc score was 4.4 ± 1.6 and the 
mean HAS-BLED score was 4.1 ± 1.1. Jalal et al. [39] reported an annual stroke/TIA rate of 
4.0% and an annual major bleeding rate of 1.3% after 75 patient-years of follow-up under 
ASA or clopidogrel monotherapy. The mean CHA
2
DS
2
-VASc score was 4.4 ± 1.3 and the mean 
HAS-BLED score 3.4 ± 0.9. Here again, the rates are in good accordance with the ones reported 
in the earlier mentioned RCTs. Initial retrospective data comparing NOAC to warfarin for 
6 weeks following LAAC showed comparable rates for device-related thrombus, composite 
of thromboembolism or device-related thrombosis and postprocedural bleeding events [65].
In summary, LAAC with different devices was proven to be effective and safe or, in the long 
run, even superior to long-term warfarin treatment in respect to all-cause and cardiovascular 
mortality when it is combined with a 45-day warfarin intake following procedure. Moreover, 
LAAC could be shown to be more effective and less costly relative to warfarin and NOACs 
in recent analyses [80, 81]. LAAC was dominant over NOACs by year 5 and warfarin by 
year 10 [80].
2.6. Perspectives
On this basis, meanwhile, the LAAC procedure has found its status in clinical practice. Due 
to the inherent character of complications regarding any interventional cardiac procedure, it 
is unlikely that complication rates will further strongly decrease and, therefore, an individu-
alized and risk-tailored approach in patient selection is a crucial step prior to the patient’s 
transfer to the catheterization laboratory. It is hoped that further studies will focus on the 
identification of patients who will derive the most benefit from an interventional approach 
and will help to better characterize the term “contraindication for long-term OAC” [82].
As more and more patients will be implanted which are even ineligible for a short-term OAC 
treatment, the alternatives, i.e., DAPT and single antiplatelet agents following LAAC, have 
to be further evaluated. In this context, the knowledge of the optimal duration of DAPT and 
about the possibility of discontinuing any antithrombotic medication will help to treat certain 
very high-risk patients based on reliable data.
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Unsolved questions derived from the postprocedural practice are the relevance of paradevice leaks 
especially ≥ 5 mm revealed during follow-up imaging procedures and the related need for action. 
Moreover, the value of CT angiography for device surveillance is not conclusively clarified yet.
But the most important would be to thoroughly compare LAAC to different NOACs as these 
substances currently are clearly recommended in AF patients without contraindications by 
the European guidelines [3]. Initial data show that the interventional approach does not need 
to be hidden away [83].
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